CN1433755A - Long-acting tretnoin intraocular slow-releasing system - Google Patents
Long-acting tretnoin intraocular slow-releasing system Download PDFInfo
- Publication number
- CN1433755A CN1433755A CN 02102477 CN02102477A CN1433755A CN 1433755 A CN1433755 A CN 1433755A CN 02102477 CN02102477 CN 02102477 CN 02102477 A CN02102477 A CN 02102477A CN 1433755 A CN1433755 A CN 1433755A
- Authority
- CN
- China
- Prior art keywords
- acting
- slow
- tretnoin
- retinoic acid
- long
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a long-acting tretinoin intraocular slow-releasing system, including tretinoin and medicinal carrier, their weight ratio is 0.1:0.9-0.9:0.1, the medicinal carrier can be synthetic biodegradable high-molecular material, natural biodegradable high-molecular material or their mixture. The medicine-releasing period of said invented long-acting tretinoin slow-releasing system is one week to one year. It has the important regulation action for proliferation and differentiation of cell, can influence differentiation and proliferation of tissue cell so as to can inhibit the growth of retinal pigment epithelial cell and fibroblast and production of PVR.
Description
Technical field
The present invention relates to a kind of body and be implanted into pharmaceutical preparation, specially refer to a kind of with the long-acting tretnoin intraocular slow-releasing system of biodegradated polymer materal as pharmaceutical carrier.
Background technology
(Proliferative Vitreoretinopathy is to occur in rhegmatogenous detachment of retina PVR) to PVR, or ophthalmic cell proliferation, fibrous membrane shrink the pathological process that finally causes detachment of retina behind the penetration injuries of eyeball.PVR is the main cause of surgery of retinal detachment failure, also is the final bad result that many serious ocular injury are repaired.Although use the vitreous excision operation now the treatment success rate of PVR is improved a lot, still have patient's postoperative that PVR can take place once more up to 7-10%.Operative treatment repeatedly not only can reduce the success rate of operation of reattachment of retina, and can increase the recurrent probability of PVR.Therefore prevent the generation of PVR to have even more important meaning than treatment PVR.
Existing understanding is the excessive reparation that results from ophthalmic of PVR.Under some pathologic conditions, excessive condensation, frequent roof pressure sclera etc. have triggered the repair process of damage in retinal hole generation, the art, thereby cause retinal pigment epithelium (Retinal Pigment Epithelium, RPE) free, destroy blood-retina barrier simultaneously, changed normal extracellular matrix, free retinal pigment epithelium is bred in a large number, the fibroblast sample takes place then to be become, secretion and give expression to multiple somatomedin and receptor thereof, thus influence is as the propagation of other cells such as glial cell, fibroblast.Blood-retina barrier is destroyed new extracellular matrix and the intercellular continuous effect that the back forms, also will influence the form of retinal pigment epithelium, cause in the vitreous body and the formation of retinal surface fibrous membrane, the further contraction of fibrous membrane then can cause amphiblestroid disengaging.
Proliferative vitreoretinopathy is with fibrous membrane propagation, the contraction of vitreous chamber and retinal surface, and finally causing detachment of retina is feature.Wherein retinal pigment epithelium is the main component of fiber propagation film, is playing significant feature aspect startup, development and the healing of proliferative vitreoretinopathy.This process is similar to the cicatrix contraction process at other positions of health, also can roughly be divided into inflammatory phase, cellular proliferative stage and cicatrix systole three phases.Therefore if can block the development of retinopathy in preceding two stages by medicine, just can finally avoid causing detachment of retina owing to (cicatrix) proliferative shrinks.
In view of the important function of retinal pigment epithelium in proliferative vitreoretinopathy,, will be the effective treatment measure that suppresses the PVR development with the medicine that suppresses retinal pigment epithelium cell proliferation, attaching and contraction.Daunomycin, amycin, 5-fluorouracil, colchicine etc. all are the active drugs that can suppress retinal pigment epithelium cell proliferation, attaching and contraction, but they mostly are the medicine of antitumor, antimetabolic greatly, toxic and side effects to normal structure is bigger, and the safety that they are used within the eye spectrum is also narrow, thereby has limited application clinically.The growth inhibitor of tyrosine kinase inhibitor endotheliocytes such as (Genistein) and tumor cell also has the function that suppresses the retinal pigment epithelium growth, suppresses the proliferative vitreoretinopathy generation, but they all also are in conceptual phase at present, fail to be applied clinical.In addition, glucocorticoid also is to use anti-inflammatory drug more widely, it is clear and definite in ophthalmic applications curative effect and toxic and side effects, stable blood-retina barrier is arranged, reduce tissue fluid and ooze out effect with cell infiltration, and is significant to the startup of blocking-up proliferative vitreoretinopathy.
(Retinoic Acid is the derivant of vitamin A RA) to retinoic acid, is the active metabolite of the interior vitamin A that forms naturally of a class body, and is little to organizing toxic and side effects, has been applied to the clinical treatment of xerophthalmia.The propagation of retinoic acid pair cell, differentiation have important regulatory role, can influence the generation of multiple histiocytic differentiation and propagation, inhibition retinal pigment epithelium, growth of fibroblasts and proliferative vitreoretinopathy, but because the existence of blood-ocular barrier, the whole body application is difficult in the ophthalmic part and reaches effective treatment concentration.And PVR is a kind of chronic disease, and long-term topical application can be made troubles and the generation of complication.Therefore how can be effectively, can make things convenient for not only but also can not produce sequela ground to use retinoic acid be still unsolved so far problem.
The slow-released system that body is implanted into medicine is a kind of novel medicament preparation, has the influence that is not subjected to body fluid flushing, dilution, and dosage is few, and can slowly discharge the characteristics of medicine for a long time in vivo; Particularly, can reach very high medication effect to the position of drug absorption difficulty.The appearance of drug sustained release system just is being subjected to global attracting attention.Yet because the problem of pharmaceutical carrier never solves, therefore up to now, the retinoic acid body with long-term release function is implanted into preparation and can't comes out.
The slow-released system that body is implanted into medicine mainly is grouped into by medicine and two kinds of one-tenth of pharmaceutical carrier; pharmaceutical carrier plays protection and control rate to the release of medicine, thereby reaches effect (Jani P., the J.Pharm.Pharmacol. that can discharge for a long time in vivo; 1990,41:821).Pharmaceutical carrier must have certain permeability to medicine, do not interact with medicine, in addition, because the slow-released system of medicine is to implant for a long time to carry out drug release, therefore the slow-released system of medicine must have the good biocompatibility of body, body is not produced effects such as inflammation, stimulation, sensitization.Such drug carrier material can be satisfied and biologically inert macromolecule and Biodegradable macromolecular material two classes can be divided into again.Silicone rubber, polyurethane etc. all are the biologically inert macromolecular materials of being used widely at medical domain, has excellent biological compatibility, be applied to preparing cardiac valve interventional therapy intubate etc., also be used to simultaneously the pharmaceutical carrier of slow releasing pharmaceutical such as long acting contraceptive.Yet with this class bio-inert material during as pharmaceutical carrier, though can keep the long-term slow release effect of medicine, and can not produce the problem of biocompatibility such as inflammation, stimulation and sensitization to body, but owing to increase along with the time, the continuous minimizing of content of dispersion in the medicament, drug releasing rate and burst size also can constantly descend, so therefore the release dosage of medicine can't guarantee constant drug dose in time in continuous minimizing; Because the biologically inert of these materials also can not change in vivo, therefore after drug release is intact, also must in body, take out again, in addition in order to avoid stay in the body and to exert an adverse impact as foreign body.
Another kind of is Biodegradable polymer drug carrier.Biodegradable polymer drug carrier is in drug release, because the effect of intravital physiological environment (body temperature, body fluid, enzyme etc.), carrier material is also constantly degraded, molecular weight diminishes, it is loose that structure becomes, so that finally be degraded to micromolecule or monomer, absorbed or metabolism by body, therefore be pharmaceutical carrier with such material, the taking-up of after drug release is intact, can performing the operation again.In addition, because material is along with degraded, structure becomes loose and makes that medicine is easier therefrom to be discharged, thereby the trend that release amount of medicine is increased is arranged.When owing to contain the minimizing of the caused drug release dosage of minimizing of medicine when consistent with the amount of the release amount of medicine that causes by degraded increase, just can realize the constant release of medicine, this be when being pharmaceutical carrier with the biologically inert macromolecule the drug release behavior (Wang Shenguo that can not realize, chemistry circular 1997,2:45).
Summary of the invention
The object of the present invention is to provide a kind of long-acting tretnoin intraocular slow-releasing system, the disposable implantation of this system can be permanently effective, drug level is stable, the bioavailability height can influence the generation of histiocytic differentiation and propagation, inhibition retinal pigment epithelium, growth of fibroblasts and proliferative vitreoretinopathy.
For achieving the above object, the present invention adopts the sustained release carrier of water-insoluble biodegradation high molecular as fat-soluble retinoic acid, and retinoic acid is carried out embedding and the retinoic acid slow releasing preparation made.
Retinoic acid slow-released system of the present invention comprises medicine and pharmaceutical carrier, and the two is 0.1 by weight: 0.9-0.9: 0.1.Described pharmaceutical carrier be have excellent biological compatibility, have certain intensity, the synthesising biological degraded macromolecular material of consistency and elasticity, natural biological degraded macromolecular material or synthesising biological degraded macromolecular material be with the blend of natural biodegradated polymer materal.Drug sustained release system can keep certain intensity, elasticity and shape before drug release is intact, thereby and can be absorbed or excrete by natural degradation under the physiological condition in vivo by metabolism, therefore neither can become foreign body body is produced stimulation, can not make body produce foreign body reaction yet, therefore not need to go again second operation that it is taken out.Above-mentioned synthesising biological degraded macromolecular material can be the aliphatic polyester family macromolecule, they can be poly (l-lactic acid) (PLLA), poly-DL-lactic acid (PDLLA), copolymerization (L-lactic acid/DL-lactic acid) (PLLA-co-PDLLA), polyglycolic acid (PGA), copolymerization (lactic acid/glycolic) (PLGA), polycaprolactone (PCL), (glycolic/lactic acid/caprolactone) terpolymer (PGLC), polycaprolactone/polyether block copolymer (PCE), polycaprolactone/polyethers/polylactic acid terpolymer (PCEL), and other polyhydroxy acid (PHA).Above-mentioned natural biological degraded macromolecular material can be chitosan, gelatin, or their blend.
Described pharmaceutical carrier can be membranaceous, lamellar, granular, block, strip.It also can be the spongy body by above-mentioned synthetic or natural biological degraded macromolecular material by the adhesive-bonded fabric of above-mentioned natural or synthetic Biodegradable high molecular.The size of above-mentioned pharmaceutical carrier pore structure and density are controlled by the method for the method of controlling solution evaporation speed or control pore dosage or by the method for control Density.
Described retinoic acid slow-released system can be an atresia, or has the pore structure that is interconnected, and its pore size is 10 nanometers-500 micron.
Retinoic acid slow-released system of the present invention is the long-acting tretnoin slow-released system, and the release cycle is week to one year; Be not subjected to the influence of tear flushing, dilution, dosage is few, and can slowly discharge medicine for a long time within the eye; For the position of drug absorption difficulty, can reach very high medication effect.Can be used for ophthalmology, the propagation of pair cell, differentiation produce important regulatory role, thereby suppress the generation of retinal pigment epithelium, growth of fibroblasts and PVR.
The specific embodiment
By the description of following embodiment and comparative example, help further understanding of the present invention, but the present invention is not limited.
Embodiment 1,
Copolymerization (lactic acid/glycolic) is (molecular weight 110,000) 15 parts (PLGA), and with adding 10 parts in retinoic acid powder after 20 parts of dissolvings of dichloromethane, the politef mould is injected in the back that stirs, and the control air velocity makes the dichloromethane volatilization.After treating bone dry, this copolymerization (lactic acid/glycolic) drug sustained release system that contains retinoic acid is taken off from the politef mould, in the room temperature vacuum drying oven, keep 48 hours to eliminate solvent fully, to obtain thickness be 2 millimeters, be the lamellar medicament of 10 nanometer small structures, and the reuse aperture is that to be washed into thick be that 2 millimeters, diameter are 2 millimeters retinoic acid slow-released system to 2 millimeters punch die.With this retinoic acid slow-releasing system with 24 hours sterilizations of epoxyethane fumigation, again place 1 week the back implant in the vitreous chamber of lagophthalmos.
The perusal of postoperative and local histopathological examination result show: the reaction of optical fundus NIP; Vitreous chamber and retina do not see that pathologic changes: cornea, crystalline lens transparency and reaction of iris are normal: find no corneal edema, iris new vessels, atrophy or downright bad phenomenon, intraocular pressure is also normal, the perioperatively no change.In addition, local organization pathological examination result shows that cornea, iris, the corpus ciliare at position, retinoic acid slow-released system place do not have obvious inflammatory cell infiltration, and inorganization degeneration and downright bad performance prove that thus the ophthalmic biocompatibility of retinoic acid slow-released system is good.And the effect of non-stimulated retinal pigment epithelium, fibroblast proliferation.
In addition, in 8 weeks after the retinoic acid slow-released system is implanted, kept certain density retinoic acid in the aqueous humor, this retinoic acid slow-released system can take out implanting the back complete obiteration of 8 weeks again always.
Embodiment 2,
Press method and the step of embodiment 1, but adopt 4 parts of 10 parts of poly-DL-lactic acid (PDLLA) (molecular weight 60,000), 20 parts of dichloromethane and retinoic acid, make diameter and be 2 millimeters medicine rod, obtaining diameter and be 2 millimeters, pore structure is the medicine rod of 10 nanometers, keeps 48 hours to be cut into the retinoic acid slow-released system of 2 millimeters long after eliminating solvent fully again in the room temperature vacuum drying oven.With this retinoic acid slow-released system with 24 hours sterilizations of epoxyethane fumigation, again place 1 week the back implant in the vitreous chamber of lagophthalmos with embodiment 1 method.The perusal of postoperative and local histopathological examination result show, the retinoic acid slow-released system has good ophthalmic biocompatibility, retinoic acid can be kept finite concentration in after the implantation 10 week in aqueous humor, and the back retinoic acid slow-released system complete obiteration of 14 weeks can be taken out again.
Embodiment 3,
Press method and the step of embodiment 1, but adopting (by Chinese invention patent application number 99105984.0 methods preparations) 10 parts of (glycolic/lactic acid/caprolactone) terpolymers (PGLC) (molecular weight 80,000), 18 parts of dichloromethane and 9 parts of retinoic acid, making each length of side is 10 millimeters block, and maintenance 48 hours is to be cut into 2 millimeters square retinoic acid slow-released systems again after eliminating solvent fully in the room temperature vacuum drying oven.With this retinoic acid slow-released system with 24 hours sterilizations of epoxyethane fumigation, again place 1 week the back implant in the vitreous chamber of lagophthalmos with embodiment 1 method.
The perusal of postoperative and local histopathological examination result show that the retinoic acid slow-released system has good ophthalmic biocompatibility, retinoic acid can be kept finite concentration in after the implantation 10 week in aqueous humor, the back retinoic acid slow-released system complete obiteration of 10 weeks can be taken out again.
Embodiment 4,
With embodiment 1 same procedure and step, but adopt (press Chinese invention patent ZL 92113100.3 methods preparations) polycaprolactone/polyether block copolymer (PCE) (molecular weight 80,000) to prepare, obtaining the pore structure size is the retinoic acid slow-released system of 10 nanometers, with 24 hours sterilizations of epoxyethane fumigation, again place 1 week the back implant in the vitreous chamber of lagophthalmos.
The perusal of postoperative and local histopathological examination result show that the retinoic acid slow-released system has good ophthalmic biocompatibility, retinoic acid can be kept finite concentration in 1 year after the implantation in aqueous humor, the complete obiteration of retinoic acid slow-released system can be taken out again after 1 year.
Embodiment 5,
With embodiment 1 same procedure and step, but adopt (press Chinese invention patent application number 98102212X method preparation) polycaprolactone/polyethers/polylactic acid terpolymer (PCEL) (molecular weight 90,000) to prepare, obtaining the pore structure size is the retinoic acid slow-released system of 50 nanometers, with 24 hours sterilizations of epoxyethane fumigation, again place 1 week the back implant in the vitreous chamber of lagophthalmos.
The perusal of postoperative and local histopathological examination result show that the retinoic acid preparation has good ophthalmic biocompatibility, retinoic acid can be kept finite concentration in after the implantation 30 week in aqueous humor, the back retinoic acid slow-released system complete obiteration of 40 weeks can be taken out again.
Embodiment 6,
With embodiment 2 same procedure and step, press method and the step of embodiment 4, but adopt the poly (l-lactic acid) (PLLA) (molecular weight 60,000) (95% weight) and the mixture of chitin (5% weight) to prepare, obtain the pore structure size and be 15 microns retinoic acid slow-released system, with 24 hours sterilizations of epoxyethane fumigation, again place 1 week the back implant in the vitreous chamber of lagophthalmos.
The perusal of postoperative and local histopathological examination result show, the retinoic acid slow-released system has good ophthalmic biocompatibility, retinoic acid can be kept finite concentration in after the implantation 50 week in aqueous humor, and the complete obiteration of retinoic acid slow-released system can be taken out again after 1 year.
Embodiment 7,
Method and step with embodiment 6, but adopt the poly-DL-lactic acid (PDLLA) (molecular weight 60,000) (95% weight) and the mixture of collagen (5% weight) to prepare, obtain the pore structure size and be 10 microns retinoic acid slow-released system, with 24 hours sterilizations of epoxyethane fumigation, again place 1 week the back implant in the vitreous chamber of lagophthalmos.
The perusal of postoperative and local histopathological examination result show that the retinoic acid slow-released system has good ophthalmic biocompatibility, retinoic acid can be kept finite concentration in after the implantation 20 week in aqueous humor, the back retinoic acid slow-released system complete obiteration of 20 weeks can be taken out again.
Reference examples 1:
With polyurethane be carrier, method for making, consumption and the step by example 3 prepares the retinoic acid slow-released system fully.Postoperative perusal and local histopathological examination show that the retinoic acid slow-released system has good ophthalmic biocompatibility, and it is finite concentration at aqueous humor that 15 after the implantation can be kept retinoic acid in week, detect in the aqueous humor during by six months less than there being retinoic acid to exist.But 1 year preparation of postoperative still is present in the vitreous chamber, and external form, size and intensity no change, the taking-up of therefore must performing the operation again.
Reference examples 2:
The method that is injected into the fibrocyte suspension with vitreous excision associating vitreous chamber is manufactured lagophthalmos proliferative vitreoretinopathy model.Be implanted into retinoic acid slow-released system and the not blank carrier of pastille at vitreous chamber the same period.Postoperative 1 month, the lagophthalmos of implantation retinoic acid slow-released system only have 7% very light detachment of retina has taken place, and serious total detachment of retina has all taken place in the lagophthalmos of blank group.Two groups relatively have significant differences.
Claims (7)
1, a kind of long-acting tretnoin intraocular slow-releasing system comprises retinoic acid and pharmaceutical carrier, it is characterized in that, the weight ratio of retinoic acid and pharmaceutical carrier is 0.1: 0.9-0.9: 0.1; Pharmaceutical carrier is synthesising biological degraded macromolecular material, natural biological degraded macromolecular material or their blend.
According to the described long-acting tretnoin intraocular slow-releasing system of claim 1, it is characterized in that 2, described synthesising biological degraded macromolecular material is the aliphatic polyester family macromolecule; Described natural biological degraded macromolecular material is chitosan and/or gelatin.
According to the described long-acting tretnoin intraocular slow-releasing system of claim 2, it is characterized in that 3, described aliphatic polyester family macromolecule is polyhydroxy acid (PHA).
4, according to the described long-acting tretnoin intraocular slow-releasing system of claim 2, it is characterized in that described aliphatic polyester family macromolecule is poly (l-lactic acid), poly-DL-lactic acid, copolymerization (L-lactic acid/DL-lactic acid), polyglycolic acid, copolymerization (lactic acid/glycolic), polycaprolactone, (glycolic/lactic acid/caprolactone) terpolymer, polycaprolactone/polyether block copolymer and/or polycaprolactone/polyethers/polylactic acid terpolymer.
According to the described long-acting tretnoin intraocular slow-releasing system of claim 1, it is characterized in that 5, described long-acting tretnoin slow-released system has the pore structure that is interconnected, its pore size is 10 nanometers-500 micron.
According to the described long-acting tretnoin intraocular slow-releasing system of claim 1, it is characterized in that 6, described pharmaceutical carrier is membranaceous, lamellar, granular, bulk or strip.
7, according to claim 1,2,3 or 4 described long-acting tretnoin intraocular slow-releasing systems, it is characterized in that, described carrier is the adhesive-bonded fabric of above-mentioned natural or synthetic Biodegradable high molecular, or by above-mentioned synthetic or spongy body that the natural biological degraded macromolecular material is made.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021024774A CN1194677C (en) | 2002-01-22 | 2002-01-22 | Long-acting tretnoin intraocular slow-releasing system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021024774A CN1194677C (en) | 2002-01-22 | 2002-01-22 | Long-acting tretnoin intraocular slow-releasing system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1433755A true CN1433755A (en) | 2003-08-06 |
| CN1194677C CN1194677C (en) | 2005-03-30 |
Family
ID=27627577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021024774A Expired - Fee Related CN1194677C (en) | 2002-01-22 | 2002-01-22 | Long-acting tretnoin intraocular slow-releasing system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1194677C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100368021C (en) * | 2004-01-18 | 2008-02-13 | 北京宏医耀科技发展有限公司 | Ophthalmological anti proliferative medicine containing sodium alginate micro gel bead and convex membrane and preparing method |
| CN101390825B (en) * | 2008-10-01 | 2010-12-29 | 山东省眼科研究所 | Intra-ocular release system of voriconazole |
-
2002
- 2002-01-22 CN CNB021024774A patent/CN1194677C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100368021C (en) * | 2004-01-18 | 2008-02-13 | 北京宏医耀科技发展有限公司 | Ophthalmological anti proliferative medicine containing sodium alginate micro gel bead and convex membrane and preparing method |
| CN101390825B (en) * | 2008-10-01 | 2010-12-29 | 山东省眼科研究所 | Intra-ocular release system of voriconazole |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1194677C (en) | 2005-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9782346B2 (en) | Biodegradable ocular implant | |
| US20060024350A1 (en) | Biodegradable ocular devices, methods and systems | |
| Bernards et al. | Ocular biocompatibility and structural integrity of micro-and nanostructured poly (caprolactone) films | |
| RU2749426C2 (en) | Non-invasive medicine delivery technique using eye inlay | |
| US11517422B2 (en) | Intraocular implants comprising drug-eluting materials with time release characteristics | |
| KR19990022212A (en) | Improved formulation to control drug release by mixing hydrophilic and hydrophobic agents | |
| BRPI0708622A2 (en) | eye therapy using sirtuin activating agents | |
| EP3324944A1 (en) | Intravitreal drug delivery systems for the treatment of ocular conditions | |
| CN102233129A (en) | Long-acting sustained release preparation for preventing or treating retinal damage, and preparation method thereof | |
| CN1204919C (en) | Long-acting intra-ocular release system of cyclosporin | |
| CN1194677C (en) | Long-acting tretnoin intraocular slow-releasing system | |
| CN1158084C (en) | Long-ncting heparin intraocular slow-released system | |
| CN1634046A (en) | Use of rapamycin in preparation of intraocularly embedded drug | |
| Patel et al. | Poly lactic glycolic acid (PLGA) as biodegradable polymer | |
| CN1175900C (en) | Preparation for eyes | |
| CN101259098B (en) | Long-acting low molecule heparin intraocular sustained-release system | |
| Kesarwani et al. | Ocular implants: A novel approach to ocular drug delivery | |
| CN1579396A (en) | Slow-releasing medicine inplanted in eye and use thereof | |
| WO2023180195A1 (en) | Object for drug delivery system | |
| CN100475190C (en) | Implantation slow release medicine in eyes | |
| CN116172885A (en) | Pharmaceutical preparation for resisting after-cataract and preparation method thereof | |
| CN1846700A (en) | Slow-released 5-fluorouracil system in vitreous chamber | |
| Pankoh et al. | Physical and Biological Investigation of Injectable Thai Silk Fibroin/Hyaluronic Acid Hydrogel Sustained-Releasing Dexamethasone | |
| RU2557925C1 (en) | Biodegradable multilayer implant for administering drug substances into vitreal cavity of eye | |
| WO2023088729A1 (en) | Supporting membrane and method for producing a supporting membrane |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |